News BioCardia, Inc.

Equities

BCDA

US09060U5074

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
0.392 ^USD	-1.04%		-2.00%	-40.98%

May. 14	Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 01	BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024	May. 14
BioCardia : Reports First Quarter 2024 Business Highlights and Financial Results	May. 14	PU
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024	May. 09	AQ
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes	May. 01	AQ
BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	May. 01	CI
Transcript : BioCardia, Inc. - Special Call	Apr. 30
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	Apr. 25	AQ
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	Apr. 25	CI
Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024	Mar. 27
BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results	Mar. 27	PU
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024	Mar. 20	AQ
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership	Mar. 13	AQ
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure	Mar. 13	CI
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	Mar. 12	AQ
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	Mar. 12	CI
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	Mar. 04	AQ
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	Mar. 04	CI
BioCardia, Inc. announced that it expects to receive $0.874999 million in funding	Feb. 08	CI
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	Feb. 08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioCardia, Inc.

Equities

BCDA

US09060U5074

Summary

Filters